Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (GRK1910)
Gouvernement du Canada | Canadian Institutes of Health Research (148431)
Canada Research Chairs (Signal Transduction and Molecular Pharmacology)
Received: 22 September 2020
Accepted: 18 August 2021
First Online: 10 September 2021
: The authors declare the following competing interests: some of the biosensors used in this study were licensed to Domain Therapeutics for commercial use but are freely available for academic research upon request. M.B. is the president of the scientific advisory board of Domain Therapeutics. The remaining authors declare no competing interests.